Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 dose comparison versus semaglutide for hepatic glucagon receptor activity in adults with obesity
NL-OMON60191Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1 trial of survodutide and semaglutide in obesity (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary endpoint(s). Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON60191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60191.